# Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)

> **NCT04377672** · PHASE1 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 14 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** Anti-SARS-CoV-2 Human Convalescent Plasma

## Key facts

- **NCT ID:** NCT04377672
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-28
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-12-13
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04377672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04377672, "Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04377672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*